Price$189.79+2.37 (+1.26%)
01:30 PM07:45 PM
News · 26 weeks71+25%
2026-03-012026-08-23
Mix3090d
- Insider15(50%)
- SEC Filings6(20%)
- Other6(20%)
- Analyst1(3%)
- Dividends1(3%)
- Earnings1(3%)
Latest news
25 items- INSIDEREVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- PRBD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to RetireFRANKLIN LAKES, N.J., Aug. 17, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8. Sorsher brings more than 30 years of experience leading quality organizations across world-class MedTech companies. Most recently, he served as chief quality officer at Edwards Lifesciences, where he led advancing quality excellence while supporting innovation, growth and operational performance across a complex global business. Throughout his career, Sorsher has b
- INSIDERChairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- INSIDEREVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- PRBD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT TrialEnrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgeryFRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias. The study enrolled 477 patients across 32 sites in the United States and E
- INSIDERSEC Form 4 filed by Director Huffines Robert Luther4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- INSIDERSEC Form 4 filed by Director Byington Carrie L4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- SECSEC Form 10-Q filed by Becton Dickinson and Company10-Q - BECTON DICKINSON & CO (0000010795) (Filer)
- SECBecton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BECTON DICKINSON & CO (0000010795) (Filer)
- PRBD Reports Third Quarter Fiscal 2026 Financial ResultsRevenue of $5.0 billion increased 5.4% as reported, 4.4% FXNGAAP and adjusted diluted EPS from continuing operations of $1.64 and $3.23, respectivelyYear-to-date cash from continuing operations increased 33.3% to $2.1 billion and free cash flow increased 44.6% to $1.7 billionCompany updates full-year guidance to reflect ongoing momentum, expects revenue growth toward the high end of its range and raises midpoint of adjusted diluted EPS guidanceFRANKLIN LAKES, N.J., Aug. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2026 third quarter, which ended June 30, 2026. "We delivered a strong
- PREMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launchCollaboration pairs leadership in pharmaceuticals and advanced drug delivery technology to support a consistent, reliable treatment experience for metabolic disease patients.FRANKLIN LAKES, N.J. and SÃO PAULO, July 29, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, and EMS, one of Brazil's leading pharmaceutical companies, today announced their collaboration in the launch of a semaglutide therapy in Brazil. This collaboration and launch underscore a shared commitment to addressing patients' ongoing healthcare challenges associated with chronic diseases, including obesity and type 2 diabetes.
- PRBD Board Declares DividendFRANKLIN LAKES, N.J., July 28, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.05 per common share, payable on September 30, 2026, to holders of record on September 9, 2026. The indicated annual dividend rate is $4.20 per share. About BDBD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative t
- INSIDEREVP, Chief Revenue Officer Feld Michael sold $11,785 worth of shares (75 units at $157.13) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 20,934 units (SEC Form 4)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- ANALYSTUBS initiated coverage on Becton Dickinson with a new price targetUBS initiated coverage of Becton Dickinson with a rating of Buy and set a new price target of $19.00
- SECBecton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BECTON DICKINSON & CO (0000010795) (Filer)
- PRMike Garrison to Retire from BDFRANKLIN LAKES, N.J., July 22, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Dr. Michael (Mike) Garrison has informed the company of his intent to retire after more than 20 years with BD, effective Oct. 2. Garrison is currently executive vice president and president of the Medical Essentials and BioPharma Systems segments at BD. During his tenure, Garrison held several leadership roles including executive vice president and president of BD's Medical segment, worldwide president of Medication Management Solutions and worldwide president of Su
- PRBD to Announce Financial Results for its Third Quarter of Fiscal 2026FRANKLIN LAKES, N.J., July 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, August 6, 2026 to discuss the Company's financial results for its third quarter of fiscal year 2026, which ended on June 30, 2026, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors, and a replay will be made available shortly after the call at the same website. Prior to the call, the Company will issue a news release and related presentation materials that will inclu
- INSIDEREVP & President Connected Care Muhsin Bilal was granted 14,342 shares and covered exercise/tax liability with 1,935 shares, increasing direct ownership by 43% to 41,359 units (SEC Form 4) (for withholding tax)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- SECSEC Form 11-K filed by Becton Dickinson and Company11-K - BECTON DICKINSON & CO (0000010795) (Filer)
- SECSEC Form 11-K filed by Becton Dickinson and Company11-K - BECTON DICKINSON & CO (0000010795) (Filer)
- INSIDEREVP, Chief Revenue Officer Feld Michael sold $11,460 worth of shares (75 units at $152.80) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 21,009 units (SEC Form 4)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- INSIDEREVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $160,226 worth of shares (1,100 units at $145.66) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 13,172 units (SEC Form 4)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- PRBD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion SystemRecognition from Vizient validates CentroVena One™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safetyFRANKLIN LAKES, N.J., June 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that its BD® CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient®, the nation's largest provider-driven healthcare performance improvement company. This contract recognizes products with the potential to drive meaningful improvements in healthcare delivery. The cont
- INSIDERNew insider Sinha Manish claimed ownership of 8,806 shares (SEC Form 3)3 - BECTON DICKINSON & CO (0000010795) (Issuer)
- INSIDEREVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $166,628 worth of shares (1,100 units at $151.48) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 14,272 units (SEC Form 4)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
BDX FAQ
7 questionsWhat does Becton Dickinson and Company do?
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids...Where does BDX stock trade?
Becton Dickinson and Company (BDX) is listed on NYSE.What sector and industry is BDX in?
Becton Dickinson and Company operates in the Health Care sector, Medical/Dental Instruments industry.Does BDX pay a dividend?
Yes. BDX's next ex-dividend date is 2026-09-09 with a declared cash dividend of $1.05 per share, payable 2026-09-30.What are analysts saying about BDX?
Becton Dickinson and Company has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $1900.00 price target on 2026-07-28. Recent price targets cluster around $1900.00.What companies are similar to BDX?
Notable peers in the same industry include TMO (Thermo Fisher Scientific Inc), ABT (Abbott Laboratories), SYK (Stryker Corporation), MDT (Medtronic plc.), MCK (McKesson Corporation). Compare BDX side-by-side with any of them on Quantisnow.How can I track BDX on Quantisnow?
Quantisnow aggregates Becton Dickinson and Company's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BDX to receive live email and push alerts on every new disclosure.